Nevada | 000-49616 | 88-0488686 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
11588 Sorrento Valley Road, Suite 17, San Diego, California (Address of principal executive offices)
|
92121 (Zip Code) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition. | ||||||||
Item 9.01 Financial Statements and Exhibits. | ||||||||
SIGNATURES | ||||||||
EXHIBIT 99.1 |
(c) | Exhibits. |
Exhibit No. | Description | |||||
99.1
|
Press Release dated November 11, 2005. |
Halozyme Therapeutics, Inc. |
||||
November 11, 2005 | By: | /s/ David A. Ramsay | ||
David A. Ramsay | ||||
Secretary and Chief Financial Officer | ||||